Free Writing Prospectus
Filed Pursuant to Rule 433 under the Securities Act of 1933
Issuer Free Writing Prospectus dated November 4, 2021
Relating to Preliminary Prospectus dated November 1, 2021
Registration Statement No. 333-260301
IO Biotech, Inc.
Update to Preliminary Prospectus
Issued November 1, 2021
This free writing prospectus relates to the initial public offering (the “Offering”) of common stock of IO Biotech, Inc. (the “Company”) and should be read together with the preliminary prospectus dated November 1, 2021 (the “Preliminary Prospectus”) that was included in Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-260301) (the “Registration Statement”) relating to this offering, which may be accessed through the following link:
https://www.sec.gov/Archives/edgar/data/0001865494/000119312521314634/d180178ds1a.htm
References to “IO,” “the Company,” “we” and “our” are used in the manner described in the Preliminary Prospectus.
This Free Writing Prospectus is being provided to provide the following updated information related to the Offering:
Common stock offered: | 7,150,000 | |||
Option to purchase additional shares: | 1,072,500 | |||
Price per share to the public: | $ | 14.00 | ||
Total capitalization as of June 30, 2021 (pro forma as adjusted) (in thousands): | $ | 222,123 | ||
Working capital as of June 30, 2021 (pro forma as adjusted) (in thousands): | $ | 222,085 | ||
Dilution in pro forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering: | $ | 5.99 |
The foregoing information supplements and updates the information contained in the Preliminary Prospectus and should be read together with the Preliminary Prospectus included in the Registration Statement.
The Company has filed a registration statement (including a prospectus) with the Securities and Exchange Commission, or the SEC, for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus if you request it by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Phone: +1-833-297-2926, Email: PostSaleManualRequests@broadridge.com.
